Andre Henri Goy MD, MS

Dr. Andre Henri Goy, M.D., M.S., is Physician in Chief of Hackensack Meridian Health Oncology Care Transformation Service, Chairman & Chief Physician Officer of John Theurer Cancer Center (JTCC) at Hackensack University Medical Center, Lydia Pfund Chair for Lymphoma, Academic Chairman Oncology at Hackensack Meridian School of Medicine at Seton Hall University, and Professor of Medicine at Georgetown University.

As Chief of the Division of Lymphoma at JTCC, he leads New Jersey’s largest program for lymphoma treatment and research. Dr. Goy has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris, and The Pasteur Institute.

Widely known for his work in mantle cell lymphoma, Dr. Goy was the lead investigator in the development of three FDA-approved drugs for this disease: bortezomib, lenalidomide, and ibrutinib. He participated in the pilot study of rituximab, which has improved the treatment of B-cell lymphoma, leukemia, and autoimmune disorders. In his current research, Dr. Goy is assessing biomarkers for lymphoma as well as novel anticancer agents, drug combinations, and non-chemotherapy options.

He believes that a revolution is happening in cancer medicine, driven by cell-based therapies. Under Dr. Goy's direction, JTCC became one of the few sites in the country offering chimeric antigen receptor (CAR) T-cell therapy—a highly promising immunotherapy for certain blood cancers. Dr. Goy was instrumental in developing JTCC's Tissue Bank, where samples are stored and analyzed for research. The Tumor Bank has received more than 1,600 patient consents and is now fueling innovative investigations. JTCC has also grown to become one of the largest bone marrow transplant programs in the Tri-State area.